Bacillus calmette-guerin substrain russian BCG-I live antigen is an intravesically-administered live BCG vaccine used to treat papillary urothelial cell carcinoma of the bladder. Live BCG vaccines administered intravesically have been a gold standard therapy in the adjuvant treatment of non-muscle-invasive bladder cancers for decades, used after tumor resection, and are thought to work by stimulating a local immune...
- Mechanism
- Curator reviewed · 2 references
The precise mechanism through which live BCG vaccines exert antineoplastic activity is unclear. It is likely that instillation of the vaccine into the bladder results in a non-specific immune response, involving both the innate and adaptive immune systems, followed by a local inflammatory response involving a variety of immune cells. BCG itself may exert direct cytotoxic effects on tumor cells, though its primary mechanism of action appears to be via internalization into tumor cells where it stimulates the aforementioned inflammatory pathways.
- Primary indication
- The live BCG vaccine (substrain Russian BCG-I, i.e.Curator reviewed · 2 structured indications
- First approval
- Canada, 2020
- Also known as
- Bacillus Calmette-Guérin (BCG) - strain russian BCG-I
- Brand names
Resolves to
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Bacillus calmette-guerin substrain russian BCG-I live antigen, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account